A double-blind, randomized, and placebo-controlled trial of buspirone added to risperidone in patients with chronic schizophrenia

Journal of Clinical Psychopharmacology

Volumn 30, Issue 6, 2010, Pages 678-682

  Ghaleiha, Ali ^a   Noorbala, Ahmad Ali ^b   Farnaghi, Farhad ^b   Hajiazim, Mohammad ^b   Akhondzadeh, Shahin ^b  

^a HAMADAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

5 HT1A; buspirone; chronic schizophrenia; negative symptoms

Indexed keywords

BUSPIRONE; PLACEBO; RISPERIDONE;

ADD ON THERAPY; ADULT; ARTICLE; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; NAUSEA; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; TREATMENT OUTCOME; TREMOR; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; BUSPIRONE; CHRONIC DISEASE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HOSPITALS, TEACHING; HUMANS; IRAN; MALE; PROSPECTIVE STUDIES; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEROTONIN 5-HT1 RECEPTOR AGONISTS; SEROTONIN RECEPTOR AGONISTS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78649371717     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181fa8720     Document Type: Article

References (23)

1. Mohammadi MR, Akhondzadeh S. Schizophrenia: etiology and pharmacotherapy. IDrugs. 2001;4:1167-1172.
2. Akhondzadeh S. Pharmacotherapy of schizophrenia: the past, present and future. Curr Drug Ther. 2006;1:1-7.
3. Möller HJ. Management of the negative symptoms of schizophrenia: new treatment options. CNS Drugs. 2003;17:793-823.
4. Möller HJ. Non-neuroleptic approaches to treating negative symptoms in schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2004;254:108-116.
5. Erhart SM, Marder SR, Carpenter WT. Treatment of schizophrenia negative symptoms: future prospects. Schizophr Bull. 2006;32:234-237.
6. Buckley PF, Stahl SM. Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or cul-de-sac? Acta Psychiatr Scand. 2007;115:93-100.
7. Akhondzadeh S, Mohammadi MR, Amini-Nooshabadi H, et al. Cyproheptadine in treatment of chronic schizophrenia: a double-blind, placebo-controlled study. J Clin Pharm Ther. 1999;24:49-42.
8. Akhondzadeh, S. The 5-HT hypothesis of schizophrenia. IDRUGS. 2001;4:295-300.
9. Akhondzadeh S, Malek-Hosseini M, Ghoreishi A, et al. Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:1879-1883.
10. Akhondzadeh S, Mohammadi N, Noroozian M, et al. Added ondansetron for stable schizophrenia: a double blind, placebo controlled trial. Schizophr Res. 2009;107:206-212.
11. Ichikawa J, Meltzer HY. R(R)-8-OH-DPAT, a serotonin (1A) receptor agonist, potentiated S(-)-sulpiride-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens but not striatum. J Pharmacol Exp Ther. 1999;291:1227-1232.
12. Ichikawa J, Ishii H, Bonaccorso S, et al. 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem. 2001;76:1521-1531.
13. Piskuli( D, Olver JS, Maruff P, et al. Treatment of cognitive dysfunction in chronic schizophrenia by augmentation of atypical antipsychotics with buspirone, a partial 5-HT(1A) receptor agonist. Hum Psychopharmacol. 2009:24:437-446.
14. Li XM, Perry KW, Wong DT, et al. Olanzapine increases invivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum. Psychopharmacology (Berl). 1998;136:153-161.
15. Goff DC, Midha KK, Brotman AW, et al. An open trial of buspirone added to neuroleptics in schizophrenic patients. J Clin Psychopharmacol. 1991;11:193-197.
16. Sirota P, Epstein B, Benatov R, et al. An open study of buspirone augmentation of neuroleptics in patients with schizophrenia. J Clin Psychopharmacol. 2001;21:454-455.
17. Ohlsen RI, Pilowsky LS. The place of partial agonism in psychiatry: recent developments. J Psychopharmacol. 2005;19:408-413.
18. Sumiyoshi T, Park S, Jayathilake K, et al. Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res. 2007;95:158-168.
19. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale for schizophrenia. Schizophrenia Bull. 1987;13:261-276.
20. Akhondzadeh S, Rezaei F, Larijani B, et al. Correlation between testosterone, gonadotropins and prolactin and severity of negative symptoms in male patients with chronic schizophrenia. Schizophr Res. 2006;84:405-410.
21. Akhondzadeh S, Tabatabaee M, Amini H, et al. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophr Res. 2007;90:179-185.
22. Chouinard G, Ross-Chouinard A, Annables, L, et al. Extrapyramidal Symptoms Rating Scale (abstract). Can J Neurol Sci. 1980;7:233.
23. Brody D, Adler LA, Kim T, et al. Effects of buspirone in seven schizophrenic subjects. J Clin Psychopharmacol. 1990;10:68-69.